NO954168L - Indolderivater som 5-HT1-lignende agonister for anvendelse mot migrene - Google Patents

Indolderivater som 5-HT1-lignende agonister for anvendelse mot migrene

Info

Publication number
NO954168L
NO954168L NO954168A NO954168A NO954168L NO 954168 L NO954168 L NO 954168L NO 954168 A NO954168 A NO 954168A NO 954168 A NO954168 A NO 954168A NO 954168 L NO954168 L NO 954168L
Authority
NO
Norway
Prior art keywords
alkyl
migraine
agonists
optionally
aryl
Prior art date
Application number
NO954168A
Other languages
English (en)
Other versions
NO954168D0 (no
Inventor
Martin James Wythes
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939308360A external-priority patent/GB9308360D0/en
Priority claimed from GB939324433A external-priority patent/GB9324433D0/en
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of NO954168L publication Critical patent/NO954168L/no
Publication of NO954168D0 publication Critical patent/NO954168D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelser med formel (I): farmasøytisk akseptable salter derav, og farmasøytisk akseptable solvater (inklusive hydrater) av hver entitet, hvor R1 er (A); (B); (C); (D) ; .R3 (A) (C) p (B) (D) eller CH2CH2NR3R< (E); R2 er R5R6C(OH)A eller R7COA; R3 er H, Ci-Cjalkyl, substituert alkylen, C3-C7cykloalkyl eventuelt substituert med HO, C3-C6alkenyl eventuelt substituert med aryl, C5-C7cykloalkenyl eller C3-C6- alkynyl; R4 er H eller (VCjalkyl; Rs og R* er hver uavhengig valgt fra H, C^-Cjalkyl, C^-C, perfluoralkyl og C3-C7cykloalkyl, eller sammen med karbonatomet som de er knyttet til, danner de en 3- til 7-leddet karbocyklisk eller eventuell heterocyklisk ring; R7 er Ci-Cjalkyl, substituert alkylen, C3-C7cykloalkyl eller aryl; A er en direkte binding eller eventuelt -forgrenet CVCjalkylen eller C2-C6alkenylen; og k er O, l eller 2; er selektive 5-HTj-lignende agonister som er nyttige ved behandling av migrene; migrenelignede hodepine, kronisk paroksysmal hemikrani og hodepine forbundet med vaskulære forstyrrelser.
NO954168A 1993-04-22 1995-10-19 Indolderivater som 5-HT1-lignende agonister for anvendelse mot migrene NO954168D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939308360A GB9308360D0 (en) 1993-04-22 1993-04-22 Indoles
GB939324433A GB9324433D0 (en) 1993-11-27 1993-11-27 Indoles
PCT/EP1994/001121 WO1994024127A1 (en) 1993-04-22 1994-04-11 Indole derivatives as 5-h1-like agonists for use in migraine

Publications (2)

Publication Number Publication Date
NO954168L true NO954168L (no) 1995-10-19
NO954168D0 NO954168D0 (no) 1995-10-19

Family

ID=26302791

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954168A NO954168D0 (no) 1993-04-22 1995-10-19 Indolderivater som 5-HT1-lignende agonister for anvendelse mot migrene

Country Status (21)

Country Link
US (1) US5607960A (no)
EP (1) EP0695301B1 (no)
JP (1) JP2802169B2 (no)
KR (1) KR960701865A (no)
CN (1) CN1121348A (no)
AT (1) ATE144773T1 (no)
AU (1) AU6567094A (no)
BR (1) BR9406481A (no)
CA (1) CA2157397C (no)
CZ (1) CZ274595A3 (no)
DE (1) DE69400824T2 (no)
DK (1) DK0695301T3 (no)
ES (1) ES2094653T3 (no)
FI (1) FI954944A0 (no)
GR (1) GR3021804T3 (no)
HU (1) HUT73807A (no)
IL (1) IL109337A0 (no)
NO (1) NO954168D0 (no)
NZ (1) NZ265269A (no)
PL (1) PL311204A1 (no)
WO (1) WO1994024127A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
EP0716649B1 (en) * 1993-08-31 1998-09-09 Pfizer Inc. 5-arylindole derivatives
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420503D0 (en) * 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
CZ288897A3 (cs) * 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine
CA2273328C (en) * 1996-11-26 2009-04-28 Abdelmalik Slassi 5-cyclo indole compounds as 5-ht1d receptor ligands
US5856510A (en) * 1996-12-16 1999-01-05 Allelix Biopharmaceuticals Inc. 5-alkenyl and 5-alkynyl indole compounds
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9705035D0 (en) * 1997-03-11 1997-04-30 Pharmacia & Upjohn Spa Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
EP0875513A1 (en) * 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
DE69819903T2 (de) 1997-08-09 2004-11-11 Smithkline Beecham P.L.C., Brentford Bicyclische verbindungen als liganden der 5-ht1 rezeptoren
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PT1305307E (pt) 2000-07-21 2004-09-30 Lundbeck & Co As H Derivados de indole eficazes no tratamento de doencas do sistema nervoso central
US6489512B1 (en) * 2002-06-21 2002-12-03 Rhodia Chirex Inc. Method for making aryl hydrazines and substituted indoles
DE60311000T2 (de) * 2002-12-10 2007-10-04 Merck Patent Gmbh Indolderivate und deren verwendung als 5-ht liganden
CA2508290C (en) 2002-12-20 2017-02-28 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
WO2004110492A2 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition comprising triptans and nsaids
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005066157A1 (en) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
GB0807772D0 (en) * 2008-04-29 2008-06-04 Lectus Therapeutics Ltd Calcium ion modulators and uses thereof
FR2953720B1 (fr) * 2009-12-11 2012-05-11 Oreal Utilisation de derives de benzyloxy-ethylamines comme conservateur,
CN104557957B (zh) * 2013-10-09 2017-04-19 华东师范大学 螺‑氧化吲哚环氧乙烷衍生物的合成方法
EP4100403A4 (en) * 2020-02-04 2024-01-03 Mindset Pharma Inc. 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONINERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8530507D0 (en) * 1985-12-11 1986-01-22 Glaxo Group Plc Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
RO111767B1 (ro) * 1990-10-15 1997-01-30 Pfizer Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni

Also Published As

Publication number Publication date
FI954944A (fi) 1995-10-17
NZ265269A (en) 1996-09-25
BR9406481A (pt) 1996-01-09
IL109337A0 (en) 1994-07-31
ES2094653T3 (es) 1997-01-16
EP0695301A1 (en) 1996-02-07
KR960701865A (ko) 1996-03-28
PL311204A1 (en) 1996-02-05
JP2802169B2 (ja) 1998-09-24
CN1121348A (zh) 1996-04-24
HUT73807A (en) 1996-09-30
EP0695301B1 (en) 1996-10-30
GR3021804T3 (en) 1997-02-28
NO954168D0 (no) 1995-10-19
CZ274595A3 (en) 1996-03-13
US5607960A (en) 1997-03-04
JPH08507083A (ja) 1996-07-30
FI954944A0 (fi) 1995-10-17
DE69400824D1 (de) 1996-12-05
HU9501920D0 (en) 1995-09-28
AU6567094A (en) 1994-11-08
WO1994024127A1 (en) 1994-10-27
CA2157397C (en) 1999-07-06
DK0695301T3 (da) 1996-12-09
DE69400824T2 (de) 1997-03-13
CA2157397A1 (en) 1994-10-27
ATE144773T1 (de) 1996-11-15

Similar Documents

Publication Publication Date Title
NO954168L (no) Indolderivater som 5-HT1-lignende agonister for anvendelse mot migrene
UY23657A1 (es) Procedimiento para la preparacion de derivados de indol
DK391289D0 (da) Indolderivater
YU108791A (sh) Pirazolopirimidinon antianginalna jedinjenja
DK0785933T3 (da) Indolderivater som 5HT1-lignende agonister
ATE188695T1 (de) Indolderivate als 5-alpha-reductase-1 inhibitoren
CA2192596A1 (en) 4-(6-fluoro-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety
MY103509A (en) Indole derivatives.
CA2202348A1 (en) Indole derivatives as 5ht1-like agonists
FI970397A (fi) Substituoituja 1,4-dihydroksylopent(b)indol-3(2H)-onijohdannaisia